Alloc-DOX

• Description:

  Alloc-DOX (N-Alloc doxorubicin) is a Doxorubicin (HY-15142A) prodrug. The combination of a catalyst (such as nano-palladium) and alloc-DOX leads to a decrease in cell viability and tumour growth[1][2].

• Product Name Alternative:

  N-Alloc doxorubicin

• UNSPSC:

  12352005

• Target:

  AMPK; Antibiotic; Apoptosis; Autophagy; Bacterial; HBV; HIV; Mitophagy; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/alloc-dox.html

• Purity:

  98.40

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  OC1=C (C (C2=CC=CC (OC) =C2C3=O) =O) C3=C (O) C4=C1C[C@] (C (CO) =O) (O) C[C@@H]4O[C@H]5C[C@@H] ([C@@H] ([C@@H] (O5) C) O) NC (OCC=C) =O

• Molecular Formula:

  C31H33NO13

• Molecular Weight:

  627.59

• References & Citations:

  [1]Miller MA, et al. Nano-palladium is a cellular catalyst for in vivo chemistry. Nat Commun. 2017 Jul 12;8:15906. |[2]Chen Z, et al. Bioorthogonal catalytic patch. Nat Nanotechnol. 2021 Aug;16 (8) :933-941.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  561022-65-9